The prevalence and clinical characteristics of newly diagnosed OSA patients eligible for incretin-base weight loss therapy based on SURMOUNT-OSA in Thailand.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260519003

Enrollment

2435

Registered

2026-05-19

Start date

2026-07-19

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To estimate the potential clinical benefit from Tirzepatide among obese patients with moderate-severe OSA without DM Tirzepatide, moderate-severe OSA, OSA resolusion

Interventions

Obese patient with moderate-severe OSA

Other

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age more than or equal to 18 years, 2. BMI more than or equal to 23 kg/m2, 3. Perform a sleep test due to suspected OSA

Exclusion criteria

Exclusion criteria: 1. Incomplete data

Design outcomes

Primary

Measure	Time frame
To determine the proportion of patients who meet the criteria for the SURMOUNT-OSA study. - find the proportion of patients were eligible for SURMOUNT-OSA	—

Secondary

Measure	Time frame
To determine the proportion of moderate-to-severe OSA among patients with obesity. - proportion of obese in moderate-severe OSA,To compare clinical characteristics of patients with moderate-to-severe OSA and obesity, with and without comorbid type 2 diabetes. - compare characteristic between group,To predict number of patients who could achieve OSA resolution, reaching a level at which PAP therapy may no longer be recommended. - predict resolusion of OSA,To identify clinical predictors of OSA resolution. - identify clinical predictor	—

Measure

Time frame

To determine the proportion of moderate-to-severe OSA among patients with obesity. - proportion of obese in moderate-severe OSA,To compare clinical characteristics of patients with moderate-to-severe OSA and obesity, with and without comorbid type 2 diabetes. - compare characteristic between group,To predict number of patients who could achieve OSA resolution, reaching a level at which PAP therapy may no longer be recommended. - predict resolusion of OSA,To identify clinical predictors of OSA resolution. - identify clinical predictor

—

Countries

Thailand

Contacts

Public ContactChatkarin Tepwimonpetkun

Thammasat University Hospital

chatkarin_ball@hotmail.com0891207395

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026